Early and Delayed Antiretroviral Therapy Results in Comparable Reductions in CD8+ T Cell Exhaustion Marker Expression

AIDS Research and Human Retroviruses

Volumn 33, Issue 7, 2017, Pages 658-667

  Rutishauser, Rachel Lena ^a   Hartogensis, Wendy ^a   Deguit, Christian Deo ^a,b   Krone, Melissa ^a   Hoh, Rebecca ^a   Hecht, Frederick M ^a   Pilcher, Christopher D ^a   Bacchetti, Peter ^a   Deeks, Steven G ^a   Hunt, Peter W ^a   McCune, Joseph M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

Author keywords

CD8+ T cell; Early ART; exhaustion; HIV

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT;

ADULT; ANTIRETROVIRAL THERAPY; ARTICLE; CD8+ T LYMPHOCYTE; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; EFFECTOR CELL; EXHAUSTION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MEMORY CELL; MIDDLE AGED; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEADY STATE; T LYMPHOCYTE SUBPOPULATION; TREATMENT DURATION; CHEMISTRY; COHORT ANALYSIS; IMMUNOLOGY; IMMUNOPHENOTYPING; PATHOLOGY; SECONDARY PREVENTION; YOUNG ADULT;

ADULT; ANTI-RETROVIRAL AGENTS; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; SECONDARY PREVENTION; YOUNG ADULT;

EID: 85021769517     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2016.0324     Document Type: Article

References (28)

1. Deeks SG, Kitchen CMR, Liu L, Guo H, Gascon R, Narva éz AB, Hunt P, Martin JN, Kahn JO, Levy J, et al. : Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 2004;104:942-947.
2. Yamamoto T, Price DA, Casazza JP, Ferrari G, Nason M, Chattopadhyay PK, Roederer M, Gostick E, Katsikis PD, Douek DC, et al. : Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection. Blood 2011;117: 4805-4815.
3. Boulware DR, Hullsiek KH, Puronen CE, Rupert A, Baker JV, French MA, Bohjanen PR, Novak RM, Neaton JD, Sereti I, et al. : Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis 2011;203:1637-1646.
4. French MA, King MS, Tschampa JM, da Silva BA, Landay AL: Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. J Infect Dis 2009;200:1212-1215.
5. Hunt PW, Lee SA, Siedner MJ: Immunologic biomarkers, morbidity, and mortality in treated HIV infection. J Infect Dis 2016;214 Suppl 2:S44-S50.
6. Sereti I, Krebs SJ, Phanuphak N, Fletcher JL, Slike B, Pinyakorn S, O'Connell RJ, Rupert A, Chomont N, Valcour V, et al. : Initiation of antiretroviral therapy in early HIV infection reduces but does not abrogate chronic residual inflammation. Clin Infect Dis 2016;ciw683.
7. Wada NI, Jacobson LP, Margolick JB, Breen EC, Macatangay B, Penugonda S, Martnez-Maza O, Bream JH: The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. AIDS 2015;29:463-471.
8. Chew GM, Fujita T, Webb GM, Burwitz BJ, Wu HL, Reed JS, Hammond KB, Clayton KL, Ishii N, Abdel-Mohsen M, et al. : TIGIT marks exhausted T cells, correlates with disease progression, and serves as a target for immune restoration in HIV and SIV infection. PLoS Pathog 2016;12:e1005349.
9. Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, Boulassel M-R, Delwart E, Sepulveda H, Balderas RS, et al. : Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006;12:1198-1202.
10. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, et al. : PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006;443:350-354.
11. Peretz Y, He Z, Shi Y, Yassine-Diab B, Goulet J-P, Bordi R, Filali-Mouhim A, Loubert J-B, El-Far M, Dupuy FP, et al. : CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction. PLoS Pathog 2012;8:e1002840.
12. Kuchroo VK, Anderson AC, Petrovas C: Coinhibitory receptors and CD8 T cell exhaustion in chronic infections. Curr Opin HIV AIDS 2014;9:439-445.
13. Jain V, Hartogensis W, Bacchetti P, Hunt PW, Hatano H, Sinclair E, Epling L, Lee T-H, Busch MP, McCune JM, et al. : Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis 2013;208:1202-1211.
14. Rajasuriar R, Wright E, Lewin SR: Impact of antiretroviral therapy (ART) timing on chronic immune activation/inflammation and end-organ damage. Curr Opin HIV AIDS 2015;10:35-42.
15. Krebs SJ, Ananworanich J: Immune activation during acute HIV infection and the impact of early antiretroviral therapy. Curr Opin HIV AIDS 2016;11:163-172.
16. Crowell TA, Fletcher JL, Sereti I, Pinyakorn S, Dewar R, Krebs SJ, Chomchey N, Rerknimitr R, Schuetz A, Michael NL, et al. : Initiation of antiretroviral therapy before detection of colonic infiltration by HIV reduces viral reservoirs, inflammation and immune activation. J Int AIDS Soc 2016;19:21163.
17. Cockerham LR, Jain V, Sinclair E, Glidden DV, Hartogenesis W, Hatano H, Hunt PW, Martin JN, Pilcher CD, Sekaly R, et al. : Programmed death-1 expression on CD4+ and CD8+ T cells in treated and untreated HIV disease. AIDS 2014;28:1749-1758.
18. Jensen SS, Fomsgaard A, Larsen TK, Tingstedt JL, Gerstoft J, Kronborg G, Pedersen C, Karlsson I: Initiation of antiretroviral therapy (ART) at different stages of HIV-1 disease is not associated with the proportion of exhausted CD8+ T cells. PLoS One 2015;10:e0139573.
19. Pilcher CD, Porco TC, Kassanjee R, Facente SN, Grebe E, Masciotra S, Norris P, Garrett P, Busch MP, Owen SM, Welte A: A generalizable method with improved accuracy for estimation of HIV infection duration using clinical HIV testing histories. HIV Diagnostics Conference, Atlanta, GA, March 23, 2016.
20. Masciotra S, McDougal JS, Feldman J, Sprinkle P, Wesolowski L, Owen SM: Evaluation of an alternative HIV diagnostic algorithm using specimens from seroconversion panels and persons with established HIV infections. J Clin Virol 2011;52 Suppl 1:S17-S22.
21. Masciotra S, Luo W, Youngpairoj AS, Kennedy MS, Wells S, Ambrose K, Sprinkle P, Owen SM: Performance of the Alere Determine- HIV-1/2 Ag/Ab Combo Rapid Test with specimens from HIV-1 seroconverters from the US and HIV-2 infected individuals from Ivory Coast. J Clin Virol 2013;58 Suppl 1:e54-e58.
22. Lanzavecchia A, Sallusto F: Understanding the generation and function of memory T cell subsets. Curr Opin Immunol 2005;17:326-332.
23. Romero P, Zippelius A, Kurth I, Pittet MJ, Touvrey C, Iancu EM, Corthesy P, Devevre E, Speiser DE, Rufer N: Four functionally distinct populations of human effectormemory CD8+ T lymphocytes. J Immunol 2007;178:4112-4119.
24. Wada NI, Bream JH, Martnez-Maza O, Macatangay B, Galvin SR, Margolick JB, Jacobson LP: Inflammatorybiomarkers and mortality risk among HIV-Suppressed Men: A multisite prospective cohort study. Clin Infect Dis 2016;63:984-990.
25. Lee SA, Sinclair E, Jain V, Huang Y, Epling L, Van Natta M, Meinert CL, Martin JN, McCune JM, Deeks SG, et al. : Low proportions of CD28-CD8+ T cells expressing CD57 can be reversed by early ART initiation and predict mortality in treated HIV infection. J Infect Dis 2014;210:374-382.
26. Saha B, Choudhary MC, Sarin SK: Expression of inhibitory markers is increased on effector memory T cells during hepatitis C virus/HIV coinfection as compared to hepatitis C virus or HIV monoinfection. AIDS 2013;27: 2191-2200.
27. Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, Hunt PW, Plants J, Seth A, Wilson CC, Deeks SG, et al. : Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis 2014;210:1248-1259.
28. Hunt PW, Sinclair E, Rodriguez B, Shive C, Clagett B, Funderburg N, Robinson J, Huang Y, Epling L, Martin JN, et al. : Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis 2014;210:1228-1238.